ClinicalTrials.gg
RecruitingNCT07578090Updated May 28, 2026

Regional Innovation in Chronic Disease and Elderly Care

An observational study in Hypertension, Cardiovascular Disease and Hyperlipidemia, sponsored by Fu Jen Catholic University. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Fu Jen Catholic University · Observational

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

This project aims to develop a community-based health promotion intervention model for populations at potential risk of metabolic syndrome. Through exercise training and lifestyle modifications, the project seeks to improve cardiopulmonary function and disease control, align with current public health policies, and establish an evidence-based model with strong potential for broader implementation.

Read the detailed description

Background: Hypertension, diabetes, and dyslipidemia are major risk factors for cardiovascular disease, with prevalence continuing to rise in Taiwan. These conditions are closely associated with shared risk factors such as aging, obesity, and smoking. The districts of Xinzhuang, Wugu, and Taishan in New Taipei City are densely populated and have a significant aging population. Environmental changes such as urbanization and air pollution pose threats to residents' cardiopulmonary health. Exercise interventions have been proven effective in improving blood pressure, blood glucose, and lipid profiles, as well as enhancing cardiopulmonary function and quality of life. Therefore, implementing structured and personalized exercise promotion programs in the community is of great importance for disease control and health promotion among populations with metabolic syndrome.

Methods: Participants will first undergo a one-month in-hospital conventional exercise training program, followed by an eleven-month home-based exercise intervention. During and after the intervention period, physical activity assessments and biochemical blood tests will be conducted.

Effect: This project aims to establish a community-based health promotion model for individuals at risk of hypertension, diabetes, and hyperlipidemia, centered on exercise interventions and lifestyle modifications. Through assessment, stratification, intervention, and outcome tracking, the project seeks to enhance health behaviors, self-management skills, and cardiopulmonary function in at-risk populations, thereby slowing disease progression and reducing healthcare resource utilization. The research findings will be submitted to relevant domestic and international academic conferences and SCI journals to increase Taiwan's international visibility in the fields of geriatric and "three highs" care. Additionally, the project will cultivate a new generation of healthcare professionals equipped with practical skills in preventive medicine and health promotion, strengthening interprofessional teamwork and community outreach capacity.

02

Conditions studied

  • Hypertension
  • Cardiovascular Disease
  • Hyperlipidemia
  • Hyperglycemia

Keywords

  • hypertension
  • exercise training
  • cardiovascular disease
  • hyperlipidemia
  • hyperglycemia
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 350 across 1,163 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Fu Jen Catholic University is the lead sponsor of 47 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patient of Affiliated University Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with hypertension, hyperglycemia, or hyperlipidemia who meet at least one of these criteria are eligible for enrollment.

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years
  • Patients diagnosed with neuromuscular disorders
  • Inability to perform cardiopulmonary exercise testing
  • Refusal to participate in the study
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. appendicular skeletal muscle mass index

    appendicular skeletal muscle mass (ASM) divided by height squared; low muscle mass is defined as ASMI \< 7.0 kg/m² in men and \< 5.7 kg/m² in women

    Time frame: From enrollment to the end of intervention at 12 months

  2. six minute walk test

    functional performance; higher scores mean a better outcome

    Time frame: From enrollment to the end of intervention at 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 345 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 7 months is below that.

Counting every sponsor, half of 426 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 11, 2026
StartActual
May 26, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07578090
Lead sponsor
Fu Jen Catholic University
Responsible party
Ke-Yun, Chao (Assistant Professor, Fu Jen Catholic University) — Principal investigator
First posted
May 11, 2026
Start date
May 26, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 28, 2026

Study contacts

Ke-Yun Chao, PhD
Contact
C00152@mail.fjuh.fju.edu.tw
+886-905-301-879
Ke-Yun Chao, PhD
principal investigator · Fu Jen Catholic University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion